C atecholaminergic polymorphic ventricular tachycardia (CPVT) is a life-threatening familial disorder characterized by adrenergically mediated arrhythmias in a structurally normal heart that may lead to sudden death.
C atecholaminergic polymorphic ventricular tachycardia (CPVT) is a life-threatening familial disorder characterized by adrenergically mediated arrhythmias in a structurally normal heart that may lead to sudden death. 1 Two genetic forms of CPVT have been identified: the autosomal-dominant variant caused by mutations in the cardiac ryanodine receptor type 2 (RyR2) gene 2 and the autosomal-recessive variant June 24, 2014
caused by mutations in the cardiac calsequestrin 2 (CASQ2) gene. 3 Additionally, 4 other genes have been associated with a clinical spectrum of manifestations consistent with the diagnosis of CPVT or with its phenocopies. [4] [5] [6] Interestingly, RyR2 and CASQ2 mutations induce diastolic Ca 2+ release from the sarcoplasmic reticulum (SR), leading to the development of delayed afterdepolarizations (DADs) and triggered activity (TA), which may precipitate life-threatening arrhythmias. [7] [8] [9] [10] This arrhythmogenic mechanism has been confirmed in patients during monophasic action potential recordings that documented the presence of adrenergically mediated DADs and TA in patients with CPVT. 11 CPVT, unless promptly diagnosed and treated, may be lethal, as documented by the fact that up to 30% of untreated individuals die suddenly before the fourth decade of life. 12, 13 Clinical management of CPVT is based on treatment with β-blockers, which attenuate the consequences of adrenergic stimulation, often combined with the sodium channel blocker flecainide, [14] [15] [16] which may directly inhibit TA. Patients unresponsive to this therapy are candidates for implantation of a cardioverter-defibrillator, 16 which is a most valuable life-saving therapy but presents a high rate of complications in the pediatric population. 17 Because the recurrence of life-threatening arrhythmic episodes on medications is quite common in patients with CPVT despite compliance with β-blocker therapy (25% recurrences in our unpublished data and 27% in the series by Hayashi et al 12 ) , there is a need for new therapeutic approaches and for the identification of a cure for this disease.
We have recently initiated a set of studies aimed at the development of a curative treatment for the recessive form of CPVT. In our first published study, 18 we demonstrated the feasibility of intraperitoneal CASQ2 gene delivery using an adeno-associated viral vector (AAV9) in CASQ2 knockout newborn mice. The study proved the ability of this approach to preserve physiological levels of calsequestrin 2 (CASQ2) and its related proteins, triadin and junctin, in the heart of CASQ2 knockout mice, and it showed that overexpressed CASQ2 localizes properly in the heart of mice and is able to prevent DADs, TA, and the development of life-threatening arrhythmias. 18 Despite these encouraging results, it is clear that the development of a curative strategy for CPVT applicable in the clinical setting should prove that (1) the efficacy and lack of side effects of viral gene transfer are documented not only in a knockout animal model but, most important, in a knock-in model of the human disease, (2) there is evidence for longterm maintenance of the antiarrhythmic response, and (3) the treatment is able to prevent the disease when administered in neonates and to revert all the phenotypic manifestations when therapy is administered in adults.
Accordingly, in the present study, we investigated whether the in vivo delivery of the AAV9-CASQ2 construct to homozygous knock-in CASQ2 R33Q/R33Q (R33Q) mice would meet those criteria. Our study was therefore targeted to investigate the ability of AAV9-CASQ2 to prevent the development of CPVT in R33Q mice infected at birth, to verify the efficacy of the viral gene transfer to prevent the onset of the disease after a medium and long period after a single infection delivered at birth, and to assess the ability of AAV9-CASQ2 gene delivery to revert the disease when administered to adult R33Q mice with an overt CPVT phenotype.
Methods
A more detailed description of methods is provided in the online-only Data Supplement.
Viral Construct
In the present study, we used an AAV9 carrying the complete cDNA of the murine cardiac CASQ2 cotranscribed, through an internal ribosome entry site sequence, with the green fluorescent protein (GFP) gene as previously described.
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Generation of R33Q Knock-In Mouse Model
A homozygous R33Q knock-in strain was previously generated in our laboratory. 10 Animals were bred and raised at the Charles River Laboratories (Calco, Italy) and transferred to the animal facility at the Maugeri Foundation for phenotypic characterization.
AAV9-CASQ2 Infection Procedure in R33Q Mice
The AAV recombinant virus (AAV9-CASQ2) and the empty virus (AAV9-GFP) were produced by the AAV Vector Core of the Telethon Institute of Genetics and Medicine (Napoli, Italy) according to a previously published protocol. 18 The viral titer was 2.6×10 12 genome copies per milliliter for AAV9-CASQ2 and 4.3×10 12 genome copies per milliliter for AAV9-GFP. The infection was performed by intraperitoneal injection in pups on postnatal day 3 (100 μL), which recovered until euthanasia was performed at 6, 9, or 12 months. Three-monthold mice were anesthetized with Avertin (0.025 mg/kg), and viral particles (200 μL) were injected into the tail vein and studied 2 months later. ECG recordings in mice of either sex were performed with implantable loop recorders (Data Sciences International).
In Vitro Electrophysiology
Ventricular myocytes were enzymatically dissociated through aortic retrograde perfusion. Action potentials were recorded by use of the 
Reverse-Transcription Polymerase Chain Reaction and Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted and purified from isolated myocytes, liver, lung, skeletal muscle, spleen, kidney, testis, and ovary of AAV9-CASQ2-infected R33Q and R33Q mice. Real-time polymerase chain reaction quantification of mRNA was processed and analyzed as previously described.
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Immunoblotting
Protein expression analysis was performed with the following antibodies: anti-CASQ2 (ABR), anti-triadin, 6 anti-junctin, 18 anti-RyR2 (ABR), anti-α-actinin (Sigma-Aldrich), and anti-cadherin (Sigma-Aldrich).
Immunoprecipitation
Protein-protein interaction was studied by coimmunoprecipitation with anti-triadin antibody.
6 AAV9-CASQ2-infected R33Q and R33Q hearts were washed with PBS and lysed in the presence of protease inhibitors according to the manufacturer's instructions (Dynabeads Coimmunoprecipitation Kit, Invitrogen). An unrelated anti-rabbit IgG (Promega) was used as negative control.
Immunohistochemistry
Hearts were collected and processed for paraffin embedding. The sections were incubated with hematoxylin and eosin and Masson trichrome staining. Immunohistochemical analysis was performed with an anti-GFP antibody (Santa Cruz).
Confocal Microscopy
Indirect immunofluorescent labeling of cardiac myocytes isolated from AAV9-CASQ2-infected R33Q mice was performed as previously described.
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Electron Microscopy
Fixed hearts of either sex were embedded in an epoxy resin, and ultrathin sections were cut, stained, and analyzed as previously described.
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Statistics
Data are reported as mean±SEM unless otherwise specified. Continuous variables were analyzed by the unpaired t test. Categorical variables were analyzed by contingency tables with the Fisher exact test. We used generalized linear mixed models with a binomial (1) or absent (0) in the mice. Cells, mice, and time since infection were random-effect variables, and genetic group was the explanatory variable. Model simplification was also used to obtain minimal adequate models. 19 We used the likelihood ratio test for model selection, Wald z test for comparing 2 factor levels, and Dunnett contrasts for multiple comparisons. All statistical analyses were carried out with R software. Values of P<0.05 were considered statistically significant.
Results
Results are presented for 2 sets of experiments. The data in the first sections are related to the protocol designed to test whether a single injection of the AAV9-CASQ2 delivered at birth in R33Q mice is able to prevent the development of CPVT up to 1 year of age corresponding to advanced age for mice. The second set of data relate to the protocol designed to test whether a single injection of the AAV9-CASQ2 construct in adult R33Q mice is able to revert phenotypic manifestations of CPVT.
Efficacy and Long-Term Persistence of the Effects of a Single Injection of AAV9-CASQ2 at Birth in R33Q Mice
We studied 3 groups of mice at different times (6, 9, and 12 months) after injection to characterize the effect of therapy on (1) efficiency of infection; (2) levels of CASQ2 and its associated proteins, triadin and junctin; (3) architecture of calcium release units (CRUs); (4) in vitro response of R33Q myocytes to isoproterenol; and (5) adrenergically mediated arrhythmogenesis in vivo.
Efficiency of AAV9-CASQ2 Infection
We quantified the infection rate by epifluorescent analysis in isolated ventricular cardiomyocytes in R33Q mice infected at birth with AAV9-CASQ2 (R33Q-INF). We observed an infection rate between 40% and 50% ( Figure 1A ). As depicted in Figure 1B , the viral distribution, detected by a specific anti-GFP immunohistochemistry, revealed a mosaic expression into cardiac tissues. GFP expression was quantified by real-time polymerase chain reaction in different organs. As expected for AAV9, [20] [21] [22] WT/WT (WT), R33Q, and R33Q-INF mice was analyzed 12 months after viral infection. In agreement with our previous report, 10 we documented that the homozygous R33Q mice present a major reduction in levels of CASQ2, junctin, and triadin as assessed by Western blot analysis (−62% in CASQ2, −42% in junctin, and −24% in triadin at 12 months; Figure 2A and 2B). In the R33Q-INF animals, however, there was a significant recovery of the levels of the 3 proteins (Figure 2A and 2B) . We assessed the cellular distribution of the virally induced CASQ2, showing that it correctly localized along the z lines ( Figure 2C ). A comparison of CASQ2 expression between R33Q and R33Q-INF myocytes is shown in Figure III in the online-only Data Supplement. 
Architecture of CRUs
We recently reported the presence of ultrastructural abnormalities in R33Q mice characterized by widening of the cisternae of junctional SR (jSR) and fragmentation and heterogeneity of couplons. 10, 18, 23 Furthermore, we observed an absence of the electron-dense CASQ2 polymer in the jSR cisternae.
Here, we show that infection with AVV9-CASQ2 in neonate R33Q mice prevents the development of abnormal jSR and avoids the loss of CASQ2 polymers and the enlargement of jSR cisternae (jSR width, 33±8 nm in R33Q, 24±7 nm in R33Q-INF; P<0.001; Figure 3 ). Interestingly, in mice infected with an empty AAV9 vector (R33Q-GFP), there was no rescue of the abnormal CRUs (jSR width in R33Q-GFP, 36±11 nm; Figure IV in the online-only Data Supplement).
Electrophysiological Response of R33Q Myocytes to Isoproterenol
Action potentials of paced (5 Hz) ventricular myocytes derived from WT, R33Q, and R33Q-INF mice infected at birth were recorded by patch-clamp technique to assess the arrhythmogenic response to β-adrenergic stimulation (isoproterenol 30 nmol/L) at different ages (6, 9, and 12 months). The AAV9-CASQ2 delivery achieved a striking reduction in isoproterenol-induced DADs and TA, preventing the development of the arrhythmogenic phenotype observed in myocytes isolated from R33Q mice (P<0.001, R33Q-INF versus R33Q; Figure 4 ).
Adrenergically Mediated Arrhythmogenesis In Vivo
WT, R33Q and R33Q-INF mice were instrumented with an implantable ECG recorder to compare the incidence of arrhythmias after adrenergic stimulation (epinephrine 2 mg/kg) at 6, 9, and 12 months after virally mediated AAV9-CASQ2 delivery. As shown in Figure 5A and 5B, R33Q mice presented a remarkable incidence of polymorphic and bidirectional ventricular tachycardia, whereas R33Q-INF mice showed a highly significant suppression of the arrhythmic events (P<0.001, R33Q-INF versus R33Q and R33Q-INF versus R33Q-GFP).
Ability of a Single Infection With the AAV9-CASQ2 Construct to Revert the CPVT Phenotype in Adult Symptomatic R33Q Mice
Three-month-old R33Q mice were instrumented with ECG telemetry to test for arrhythmia susceptibility after administration of epinephrine. Mice that developed either polymorphic or bidirectional ventricular tachycardia were randomized into 2 groups based on the response to this initial test: R33Q mice receiving no viral gene transfer (n=9) and R33Q mice infected with either AAV9-CASQ2 (n=13) or AAV9-GFP (empty vector; n=3). Two months after the infection, we re-exposed them to ECG challenge and performed molecular, ultrastructural, and electrophysiological assays.
Efficiency of AAV9-CASQ2 Infection
The infection rate was calculated by epifluorescent analysis of GFP expression in isolated cardiac myocytes ( Figure 6A ). AAV9-CASQ2 virus delivered in adult mice achieved an infection rate comparable to that of infected newborn mice (≈40%). Figure  VC and VD in the online-only Data Supplement). Two months after infection with AAV9-CASQ2, a normalization of the levels of expression of CASQ2, triadin, and junctin was observed ( Figure 6B ). At the same time, coimmunoprecipitation experiments with a specific anti-triadin antibody ( Figure 6C and 6D) showed that infected cells preserve and restore the physiological protein-protein interactions between triadin and CASQ2 and between triadin and junctin, respectively.
Levels of CASQ2, Triadin, and Junctin
Architecture of CRUs
We performed electron microscopy on cardiac tissue of R33Q and R33Q-INF mice. As shown in Figure 7A , the AAV9-CASQ2 infection reverted the abnormal morphology of the jSR typical of R33Q mice, inducing a significant reduction in the width of the jSR in R33Q-INF (from 34±9 nm in R33Q to 24±4 nm in R33Q-INF; P<0.001). In R33Q-INF hearts, we observed the simultaneous presence of cells with restored CRUs (likely the infected cells) and cardiomyocytes with an abnormal architecture (possibly noninfected cells; Figure 7B ).
Electrophysiological Response of R33Q Myocytes to Isoproterenol
Functional analysis was accomplished by in vitro electrophysiology on isolated cardiomyocytes derived from the hearts of R33Q, R33Q-GFP, and R33Q-INF mice ( Figure 8A ). The action potential profiles elicited at 5 Hz after β-adrenergic stimulation (isoproterenol 30 nmol/L) revealed a remarkable decrease in the percentage of DADs and TA in R33Q-INF versus R33Q cells (P<0.007 for both DADs and TA; Figure 8A and the Table) .
Adrenergically Mediated Arrhythmogenesis In Vivo
In vivo evaluation of arrhythmias susceptibility was performed by ECG recordings in R33Q, R33Q-GFP, and R33Q-INF mice 2 months after viral gene transfer treatment. An epinephrine test revealed a remarkable reduction in the occurrence of ventricular tachycardia in R33Q-INF mice compared with R33Q mice (P<0.001) and R33Q-GFP mice (P<0.05; ( Figure 8B and the Table) .
In a global evaluation of the consequence of administering a single dose of AAV-CASQ2 therapy in adult R33Q mice, we observed a complete recovery of all the phenotypic manifestations of the recessive CPVT that were present before treatment.
Discussion
The recessive form of CPVT, associated with different CASQ2 mutations, shares with the autosomal-dominant form of CPVT the same final pathway of SR Ca 2+ overload, spontaneous diastolic SR Ca 2+ release, and Ca 2+ oscillations after adrenergic stimulation that represent a highly arrhythmogenic situation. 24, 25 The complex pathogenesis of CASQ2-related CPVT is a remarkable example of how a single gene mutation, which determines primarily drastic instability and a reduction in the mutant protein, triggers a cascade of events resulting in biophysical, proteomic, and ultrastructural abnormalities. 9, 10, 22 Our group has recently demonstrated that it is possible to correct the CPVT phenotype in CASQ2 knockout mice by AAV transfer of the CASQ2 gene. 18 However, to replicate what happens in the human form of the disease, we tested our gene therapy approach in the homozygous R33Q knock-in mouse model, characterized by the expression of an endogenous defective CASQ2 protein. 10 This model is a bigger challenge for the viral gene transfer approach because it is difficult to predict whether the overexpressed wild-type CASQ2 would polymerize with the mutant protein to rescue the composite phenotypic manifestations of the disease.
Data presented in this work prove that a single administration of the viral construct AAV9-CASQ2 displays long-lasting efficiency in mice infected at birth and is able to revert the phenotype in adult symptomatic mice. These 2 protocols simulate 2 distinct clinical scenarios for the delivery of gene therapy to infants genotyped at birth and to symptomatic individuals diagnosed later in life.
The AAV9-CASQ2 infection rate in cardiac cells resulted in ≈40% after delivery of the construct in both neonates and adult animals. The functional characterizations combining in vivo and in vitro electrophysiology demonstrated comparable features in AAV infection in newborns and in symptomatic adults, proving that the efficacy of the viral delivery of CASQ2 is independent of the time of administration of the viral construct. As expected, the virus localized preferentially into the heart, as demonstrated by real-time GFP expression and immunohistochemical analysis. The systemic administration of AAV9-CASQ2 was able to restore the physiological protein levels of CASQ2, triadin, and junctin, providing evidence of their high interdependence and the appropriate localization in the cardiac myocytes.
In addition, coimmunoprecipitation in infected R33Q adult mice suggests that the overexpressed CASQ2 is also able to retain the physiological protein-protein interaction between triadin and CASQ2 and to restore the molecular binding, missed in R33Q mice, between triadin and junctin. Interestingly, we have shown that our gene therapy strategy is able to recover protein levels and to revert the jSR widening and fragmentation 23 seen in CRUs of R33Q. 10 It is also remarkable that electron microscopy allowed to appreciate the correct localization of the overexpressed CASQ2 in the jSR as documented by the reappearance of the chain-like polymers of CASQ2 in the jSR. 26, 27 A puzzling question raised by our study is why, even though the AAV9-CASQ2 construct does not reach all cardiac cells, it induces a remarkable antiarrhythmic efficacy. We believe that biophysical properties that regulate the propagation of the action potential in the heart may provide an explanation for this apparently surprising effect. Accordingly, for a triggered action potential to elicit a premature ventricular complex, it has to be able to propagate to adjacent cells. Because action potential propagation follows the "source-sink" relationship, both active and passive properties of the cardiac tissue determine whether an action potential is able to travel from cell to cell. It is only when adjacent myocytes develop synchronous DADs that the summation of the multiple depolarizations allows propagation of a triggered action potential to the entire heart. The experimental demonstration of this concept has been provided in a most elegant in silico study by Xie et al. 28 These authors calculated the number of adjacent cells required for a DAD to generate an action potential and showed that an afterdepolarization is suppressed unless a sufficient number of the neighboring myocytes develop an afterdepolarization on the same beat. Therefore, to prevent propagation of triggered beats, it is not required that all cells are rescued; it is enough that a fraction of them impair propagation of action potentials to prevent life-threatening arrhythmias.
The need for novel and more effective therapies for CPVT and the efficacy observed in our recessive CPVT animal models of CASQ2 viral gene delivery open the door to gene therapy for CPVT. The recent Calcium Up-Regulation by Percutaneous Administration of Gene in Cardiac Disease (CUPID) study showed the safety and efficacy of AAV-mediated cardiac delivery of the sarcoplasmic/endoplasmic reticulum Ca 2+ ATPase 2a (SERCA2a) gene in heart failure patients. 29 These results, combined with the first marketing approval by European Medicines Agency of an AAV gene therapy for lipoprotein lipase deficiency, 30 ,31 provide a solid rationale for planning the clinical testing of AAV gene therapy for other diseases with unmet clinical needs such as recessive CPVT. 
SUPPLEMENTAL MATERIAL
Supplemental Methods
In vivo pharmacological challenge
In vivo ECG recordings were performed using subcutaneous devices (Data Sciences International). Baseline ECGs were recorded for 30 minutes followed by intraperitoneal Epinephrine injection (2 mg/Kg) and an additional 30 minutes of continuous recording. All the animals were studied according to the protocols approved by the Animal Care and Use committee at the Maugeri Foundation, Pavia.
Immunohistochemistry
Hearts were collected and processed for paraffin embedding. 
Isolation of Adult Mice Ventricular Myocytes
Ventricular myocytes were isolated using an established enzymatic digestion protocol 1 from wild type, R33Q, R33Q-INF and R33Q-GFP mice with the AAV9-CASQ2 construct of either sex at different ages.
Action potential recordings in Isolated Ventricular Myocytes
Isolated ventricular myocytes were seeded on a glass bottom perfusion chamber 
